Brepocitinib Overview & RVT-3101 Update

Expected Phase 3 Dose Shows Clinically Meaningful Improvements in Biomarker Positive Patients Beyond Those Seen in the Overall Population Clinical Remission (Modified Mayo) Endoscopic Improvement ■RVT-3101 Placebo RVT-3101 Placebo 45% Pbo-adj A 30% p = 0.02 65% 60% 40% 55% 35% Pbo-adj A 20% p = 0.01 40% Pbo-adj A = 46% p = 0.0005 56% 50% Pbo-adj A = 22% 45% 30% p = 0.01 31% 40% 25% 40% 35% 30% 20% 25% 15% 20% 10% 12% 15% 19% 10% 10% 5% 10% 5% 0% 0% All-Comers Biomarker Positive All-Comers Expected P3 Dose Expected P3 Dose Expected P3 Dose Biomarker Positive Expected P3 Dose roivant 10 For investor audiences only

View entire presentation